Core Viewpoint - Bristol-Myers Squibb has signed an agreement to sell its 60% stake in the Shanghai-based joint venture SASS, marking a significant shift in its strategy to optimize its asset layout in China [1][2]. Group 1: Company Actions - The sale of the SASS factory reflects Bristol-Myers Squibb's commitment to its production strategy, which aims to balance internal resources through strong external partnerships [1]. - The SASS factory primarily operates mature products, including various medications that have seen reduced profitability due to China's centralized procurement policies [2][3]. - Bristol-Myers Squibb is focusing on innovation and plans to introduce nearly 30 innovative products or indications by 2025 as part of its "China 2030 Strategy" [3]. Group 2: Market Context - The trend of multinational pharmaceutical companies optimizing their asset layouts in China is evident, with other companies like Eli Lilly and GSK also divesting mature product lines [2]. - The Chinese government has introduced policies favoring innovative drugs, encouraging pharmaceutical companies to shift focus from mature products to innovative therapies [2][3]. - Bristol-Myers Squibb aims to enhance drug accessibility and become a leader in oncology, hematology, and immunology in China [3]. Group 3: Product Development - Bristol-Myers Squibb was the first to introduce an immunotherapy drug for cancer treatment in China, but it has struggled to gain market traction due to high costs and lack of insurance coverage [4]. - The company is working to change the development strategy for its PD-1 monoclonal antibody, aiming to include it in the national medical insurance directory [5].

Group 1: Company Insights - E Fund recently conducted research on seven listed companies, highlighting significant growth in revenue for Yuanjie Technology, particularly in the demand for 400G/800G optical modules, with expectations for substantial growth in the second half of 2025 [1] - Weisi Medical's lower limb exoskeleton device has been included in the medical insurance directory, and its electrical stimulation products are primarily used in obstetrics and gynecology departments [1] - Dekoli experienced rapid growth in computing power demand but faced challenges with capacity and supply chain resources, leading to insufficient order fulfillment [1] - Ningbo Jingda's performance was slightly impacted by international trade factors, but it saw a double-digit growth in orders in the second quarter, with a 70% increase in export orders after acquiring Wuxi Micro Research [2] - Xinmai Medical reported a revenue of 714 million yuan and a net profit of 315 million yuan, with overseas revenue growing over 95% [3] - Kehua Data achieved a revenue of 3.733 billion yuan, with a 0.06% year-on-year growth, and a 16.77% increase in data center business revenue [4] Group 2: Industry Trends - The demand for high-power CW light sources and high-speed EML technology is increasing, with companies focusing on core technology breakthroughs and maintaining high gross profit margins [1] - The integration of advanced technologies in manufacturing, such as high-frequency pipe-making and rolling machines, is being pursued to promote import substitution in the industry [2] - The development of new energy solutions, including 2000V450kW inverters, is being accelerated to serve various sectors, including state-owned enterprises [3] - The semiconductor industry is facing challenges with high R&D investments and increased financial costs, impacting profitability for companies like Dongxin [5]

Investment Rating - The industry investment rating is "Buy" (maintained) [2] Core Viewpoints - The domestic innovative drug industry is expected to reach an inflection point in 2025, transitioning from capital-driven to profit-driven trends, presenting opportunities for both performance and valuation recovery [5][28] - The basic fundamentals are showing marginal changes that continue to support a recovery in the secondary market, with innovative products being commercialized and leading innovative drug companies entering a profit cycle [6][29] - Continuous release of supportive policies for innovative drugs, including the introduction of the first Class B medical insurance directory, is expected to further expand the market scale [7][30] Summary by Sections Industry Performance - Over the past 12 months, the relative return of the industry compared to the CSI 300 index was 34.1%, with an absolute return of 53.9% [3] Investment Recommendations - The report emphasizes two main investment lines: 1. Pharma companies transitioning to innovation, which have strong performance resilience and are expected to see valuation increases. Recommended companies include Huadong Medicine, Aosaikang, and Health元 [9][30] 2. Biotech companies that are continuously growing and have potential products for overseas registration [9][30] Market Analysis and Outlook - The innovative drug sector is benefiting from significant overseas licensing deals, indicating a strong upward trend in the market. The report highlights the importance of focusing on the commercialization value of research pipelines and the impact of the 2025 national medical insurance directory negotiations [8][30] - The report notes that the innovative drug industry is entering a new profit-driven cycle, with a three-dimensional stock selection framework based on clinical demand, technology platforms, and product strength [7][30]

Market Performance - On July 1, the major stock indices in Shanghai and Shenzhen opened mixed, with the Shanghai Composite Index slightly higher and the Shenzhen Component and ChiNext Index also opening with minor gains. The Shanghai Composite Index showed a fluctuating upward trend throughout the day, closing at 3457.75 points, up 0.39%, marking a new year-to-date closing high [1] - The Shenzhen Component Index closed at 10476.29 points, up 0.11%, while the ChiNext Index closed at 2147.92 points, down 0.24%. The total trading volume for the Shanghai market was approximately 553.6 billion yuan, and for the Shenzhen market, it was about 912.5 billion yuan [1] Sector Performance - The pharmaceutical sector led the gains, with significant increases in various sub-sectors such as immunotherapy, innovative drugs, recombinant proteins, generic drugs, weight loss drugs, hepatitis concepts, and hair medical treatments. Other sectors that saw notable increases included shipbuilding, industrial gases, photolithography machines, banking, and superconducting concepts [1] - Conversely, digital currency stocks experienced significant declines, along with substantial adjustments in sectors like electronic identification, cross-border payments, and Web3 concepts [1] Institutional Insights - According to institutional views, the market is expected to experience fluctuations, with a historical 60% probability of the Shanghai Composite Index rising in July. Investors are advised to focus on defensive sectors in the early part of the month and shift attention to mid-year performance reports and policy movements later on. Key sectors to watch include technology (semiconductors, AI), military industry, and high-growth areas in mid-year reports [2] - Another institution emphasized the importance of focusing on performance-driven sectors and stable assets as the earnings season approaches, with expected growth in industries such as steel, computers, and defense [2] Policy Developments - The National Healthcare Security Administration announced that a draft for the commercial insurance innovative drug directory and the medical insurance directory will be released soon. This initiative aims to streamline the application process for companies and ensure that both directories are aligned in their adjustments [4] - The State-owned Assets Supervision and Administration Commission is accelerating the development of the new energy vehicle industry, focusing on enhancing the capabilities of young talents in intelligent development and digital marketing [5]

Group 1 - The Hong Kong stock market opened strong on the first trading day of June, with pharmaceutical stocks rising, particularly the Hong Kong Innovative Drug ETF (159567) which increased by 0.22% [1] - At least six domestic innovative drug companies announced BD transaction orders in May, indicating a trend of cross-border cooperation between Chinese and foreign pharmaceutical companies [1] - The total amount of innovative drug transactions overseas has reached $45.5 billion since the beginning of 2025, with upfront payments amounting to $2.2 billion, suggesting a potential record high for the year [1] Group 2 - Hansoh Pharmaceutical announced a licensing agreement with Regeneron Pharmaceuticals for the global exclusive rights to develop, produce, and commercialize HS-20094, excluding mainland China, Hong Kong, and Macau, with an upfront payment of $80 million [2] - The National Medical Products Administration has approved 11 new innovative drugs for market entry, with two more under priority review, which is expected to support the performance growth of related companies [2] - The pharmaceutical industry is anticipated to experience valuation recovery in 2025 due to factors such as innovative drug transactions, optimization of domestic procurement policies, and recovery of medical device tenders [2]